LADENBURG THALM/SH SH Issues Pessimistic Forecast for Crescent Capital BDC (NASDAQ:CCAP) Stock Price

Crescent Capital BDC (NASDAQ:CCAP) had its price objective dropped by analysts at LADENBURG THALM/SH SH from $15.00 to $14.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s target price would suggest a potential upside of 25.45% from the stock’s previous close.

A number of other research firms have also recently commented on CCAP. Keefe, Bruyette & Woods dropped their price objective on Crescent Capital BDC from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Tuesday, June 16th. B. Riley Financial reduced their target price on shares of Crescent Capital BDC from $13.50 to $12.50 and set a “neutral” rating on the stock in a report on Wednesday. Oppenheimer cut shares of Crescent Capital BDC from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $19.00 to $16.00 in a research note on Friday, May 15th. Wall Street Zen downgraded shares of Crescent Capital BDC from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Zacks Research raised shares of Crescent Capital BDC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.30.

Crescent Capital BDC Price Performance

CCAP stock traded down $0.28 on Wednesday, reaching $11.16. The company had a trading volume of 147,676 shares, compared to its average volume of 222,311. The company’s fifty day moving average is $11.16 and its 200 day moving average is $12.38. The company has a market cap of $411.20 million, a P/E ratio of -124.00 and a beta of 0.52. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.53 and a current ratio of 1.53. Crescent Capital BDC has a 1 year low of $10.64 and a 1 year high of $16.03.

Crescent Capital BDC (NASDAQ:CCAP) last released its quarterly earnings results on Monday, August 10th. The company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.01). Crescent Capital BDC had a positive return on equity of 8.88% and a negative net margin of 2.02%.The company had revenue of $5.12 million for the quarter, compared to analysts’ expectations of $37.12 million. On average, research analysts forecast that Crescent Capital BDC will post 1.38 earnings per share for the current year.

Insider Buying and Selling at Crescent Capital BDC

In other Crescent Capital BDC news, CEO Jason Breaux bought 5,000 shares of Crescent Capital BDC stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $11.19 per share, for a total transaction of $55,950.00. Following the completion of the transaction, the chief executive officer owned 52,636 shares of the company’s stock, valued at $588,996.84. This represents a 10.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Henry Chung bought 4,500 shares of Crescent Capital BDC stock in a transaction that occurred on Thursday, May 21st. The shares were acquired at an average price of $11.45 per share, for a total transaction of $51,525.00. Following the completion of the transaction, the president directly owned 20,722 shares of the company’s stock, valued at $237,266.90. This trade represents a 27.74% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 1.23% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Fidelity National Financial Inc. acquired a new position in shares of Crescent Capital BDC in the 2nd quarter valued at $45,922,000. Invesco Ltd. increased its holdings in shares of Crescent Capital BDC by 1,504.9% during the 4th quarter. Invesco Ltd. now owns 659,696 shares of the company’s stock worth $9,269,000 after buying an additional 618,590 shares during the last quarter. North Ground Capital increased its holdings in shares of Crescent Capital BDC by 99.8% during the 4th quarter. North Ground Capital now owns 835,312 shares of the company’s stock worth $11,736,000 after buying an additional 417,312 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Crescent Capital BDC in the 4th quarter worth $5,476,000. Finally, Closed End Fund Advisors Inc. purchased a new position in shares of Crescent Capital BDC in the 4th quarter worth $3,166,000. 49.46% of the stock is currently owned by hedge funds and other institutional investors.

More Crescent Capital BDC News

Here are the key news stories impacting Crescent Capital BDC this week:

• Positive Sentiment: Crescent Capital BDC declared a third-quarter base dividend of $0.34 per share and a $0.03 special dividend. The base payout implies an annualized yield of approximately 11.9%, which may support income-focused demand for CCAP. The ex-dividend date is September 30, with payment scheduled for October 15. Crescent Capital BDC declares dividend and special dividend
• Neutral Sentiment: Management expects leverage to return to its target range during the second half of 2026 while maintaining the $0.34 base dividend. The outlook provides some reassurance on capital management, although leverage normalization remains dependent on execution and portfolio conditions. Crescent Capital BDC leverage outlook
• Negative Sentiment: Wells Fargo lowered its price target for CCAP to $11 from $12 and assigned an “equal weight” rating, indicating limited upside and roughly 1.5% downside from the recent share price. The reduced target reflects a more cautious valuation outlook. Wells Fargo price target report
• Negative Sentiment: Crescent Capital BDC reported second-quarter earnings of $0.36 per share, below the $0.37 consensus estimate and down from $0.46 a year earlier. Reported revenue of $5.12 million was also substantially below the $37.12 million consensus figure, adding to concerns about operating performance. Crescent Capital BDC misses second-quarter estimates

Crescent Capital BDC Company Profile

Crescent Capital BDC, Inc is a closed-end, externally managed business development company that provides flexible financing solutions to middle market companies in the United States. Trading on the Nasdaq under the ticker CCAP, the firm offers investors exposure to a diversified portfolio of debt and equity instruments, targeting businesses with attractive risk-adjusted return profiles. Its primary objective is to generate current income through interest payments and potential capital appreciation via selective equity co-investments.

The company’s investment strategy emphasizes senior secured loans, unsecured second-lien loans, mezzanine debt, as well as preferred and common equity co-investments.